Skip to content

Omeros OMER Change in receivables

Change in receivables at other companies

Eli Lilly logo
Eli LillyLLY
$1.75B+225%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's change in receivables?
Omeros (OMER) reported change in receivables of $1.12M in Q1 2026.
How has Omeros's change in receivables changed year-over-year?
Omeros's change in receivables increased by 268.2% year-over-year, from -$663K to $1.12M.
What is the long-term trend for Omeros's change in receivables?
Over 2 years (2021 to 2025), Omeros's change in receivables has grown at a -69.6% compound annual growth rate (CAGR), from $34.31M to $3.18M.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.